中央實驗室市場機會、成長要素、產業趨勢分析及 2026-2035 年預測。

全球中心實驗室市場預計到 2025 年價值 41 億美元，預計到 2035 年將以 6.1% 的複合年成長率成長至 74 億美元。

受全球臨床試驗數量增加、檢測技術不斷進步以及生命科學領域研發投入不斷成長的推動，該市場正經歷穩步成長。醫院和診所日益增加的檢測服務外包也顯著促進了市場成長。儘管疾病盛行率上升導致檢測數量增加，但物流網路的改進使得檢體運輸更加快捷高效。基因組和分子檢測的擴展進一步強化了對先進中心實驗室能力的需求。此外，分散式臨床試驗模式的日益普及以及新興市場在全球臨床試驗中參與度的提高，也加劇了對標準化、高品質檢測基礎設施的需求。自動化系統、高通量分析儀、數位病理工具和先進分子檢測平台等技術進步顯著提高了營運效率、準確性和可重複性。這些進步確保了多中心臨床試驗數據品質的一致性，從而支持更可靠的藥物研發結果，並提升了中心實驗室在全球臨床研究中的策略重要性。

預計到2025年，生物標記服務領域將佔據31.3%的市場佔有率，這主要得益於醫療機構診斷和檢測服務外包需求的增加。基於生物標記的檢測在藥物研發和精準醫療中發揮著至關重要的作用，它能夠支持臨床試驗中的患者分類、治療標靶檢驗、安全性監測和治療反應評估。隨著分子、基因和蛋白質生物標記檢測技術的不斷普及，市場對標準化、高精度檢測服務的需求也日益成長。

預計到2025年，腫瘤學領域的市場規模將達到13億美元，成為中心實驗室市場的主要應用領域。腫瘤學研究高度依賴複雜的診斷測試，包括基因組分析和組織學評估，因此中心實驗室的支持對於確保各試驗點結果的一致性和準確性至關重要。隨著標靶治療、免疫療法和細胞療法的進步，對先進檢測服務的依賴性進一步增強。集中式腫瘤檢測對於現代癌症研究計畫變得不可或缺，因為它能夠提高數據可靠性、改善患者篩選流程並支援適應性臨床試驗設計。

預計2025年，美國中心實驗室市場規模將達到14億美元。該國市場擴張的驅動力主要來自疾病盛行率上升帶來的診斷需求成長，以及為提高檢查室效率和營運績效而日益普及的自動化技術。此外，對個人化醫療的重視也推動了對先進診斷和生物標記檢測服務的需求。政府和私營部門對生物醫學研究和臨床試驗的持續投入進一步促進了市場成長。同時，癌症和糖尿病等慢性疾病負擔的加重也推動了對綜合檢測服務的需求，從而支撐了美國中心實驗室基礎設施的持續需求。

目錄

第1章：調查方法

• 研究途徑
• 品質改進計劃
  • GMI人工智慧政策及對資料完整性的承諾
    • 資訊來源一致性協議
• 調查過程和可靠性評分
  • 研究路徑的組成部分
  • 評分組成部分
• 數據收集
  • 主要來源部分列表
• 資料探勘資訊來源
  • 付費資訊來源
    • 區域資訊來源
• 基本估算和計算方法
  • 基準年的計算
• 預測模型
  • 量化市場影響分析
    • 生長參數對預測的數學影響
• 關於調查透明度的補充信息
  • 資訊來源歸屬框架
  • 品質保證指標
  • 對信任的承諾

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 測試服務外包正受到越來越多的關注。
    • 測試設備的技術進步
    • 研發投資大幅成長
    • 全球臨床試驗的成長
  • 產業潛在風險與挑戰
    • 嚴格的政府法規和合規性
    • 高昂的營運成本和基礎設施成本
  • 機會
    • 人工智慧與進階分析的融合
    • 進入新興市場和低度開發市場
• 成長潛力分析
• 監理情勢（基於初步調查）
• 科技與創新趨勢
  • 當前技術趨勢
  • 新興技術
• 未來市場趨勢（基於初步研究）
• 人工智慧和生成式人工智慧對市場的影響（基於初步研究）
• 價格分析（2025 年）（基於初步調查）
• 差距分析
• 波特五力分析
• PESTEL 分析
• 政策展望

第4章 競爭情勢

• 介紹
• 企業矩陣分析
• 企業市佔率分析（基於初步研究）
  • 世界
  • 北美洲
  • 歐洲
  • 亞太地區
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依服務業分類，2022-2035年

• 生物標誌服務
• 解剖病理學/組織學
• 微生物服務
• 檢體管理及儲存
• 基因服務
• 其他服務

第6章 市場估計與預測：依應用領域分類，2022-2035年

• 腫瘤學
• 神經病學
• 循環系統
• 感染疾病
• 其他用途

第7章 市場估計與預測：依最終用途分類，2022-2035年

• 製藥和生物技術公司
• 學術研究機構
• 其他最終用戶

第8章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲（MEA）
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• ACM Global Laboratories
• BioAgilytix Labs
• Cerba Research
• Eurofins Scientific
• Frontage Laboratories
• ICON plc
• IQVIA Laboratories
• LabConnect
• Labcorp
• Lambda Therapeutic Research
• Medicover Integrated Clinical Services（MICS）
• Medpace, Inc.
• Parexel International Corporation
• Quest Diagnostics
• Thermo Fisher Scientific
• Versiti

The Global Central Lab Market was valued at USD 4.1 billion in 2025 and is estimated to grow at a CAGR of 6.1% to reach USD 7.4 billion by 2035.

The market is experiencing steady expansion driven by the rising number of global clinical trials, continuous advancements in laboratory testing technologies, and increased investment in research and development activities across the life sciences sector. Growing outsourcing of laboratory services by hospitals and clinics is also contributing significantly to market growth. Rising disease prevalence is leading to higher test volumes, while improved logistics networks are enabling faster and more efficient sample transportation. The expansion of genomic and molecular testing is further strengthening demand for advanced central laboratory capabilities. In addition, the increasing adoption of decentralized clinical trial models and the growing participation of emerging markets in global trials are reinforcing the need for standardized, high-quality laboratory infrastructure. Technological improvements such as automation systems, high-throughput analyzers, digital pathology tools, and advanced molecular testing platforms are significantly enhancing operational efficiency, accuracy, and reproducibility. These advancements are ensuring consistent data quality across multi-site clinical studies, supporting more reliable drug development outcomes, and reinforcing the strategic importance of central laboratories in global clinical research.

The biomarker services segment accounted for 31.3% share in 2025, owing to the increasing outsourcing of diagnostic and testing services by healthcare institutions. Biomarker-based testing plays a critical role in drug development and precision medicine by supporting patient classification, therapeutic target validation, safety monitoring, and treatment response evaluation across clinical trials. The rising adoption of molecular, genetic, and protein-based biomarker testing is increasing the demand for standardized, high-precision laboratory services.

The oncology segment generated USD 1.3 billion in 2025, making it the leading application area within the central lab market. Oncology research relies heavily on complex diagnostic testing, including genomic analysis and tissue-based evaluations, which require centralized laboratory support to ensure consistency and accuracy across trial sites. The growing development of targeted therapies, immunotherapies, and cell-based treatment approaches is further increasing reliance on advanced laboratory services. Centralized oncology testing enhances data reliability, improves patient selection processes, and supports adaptive clinical trial designs, making it essential for modern cancer research programs.

U.S. Central Lab Market was valued at USD 1.4 billion in 2025. Market expansion in the country is supported by rising diagnostic demand driven by increasing disease prevalence and the growing adoption of automation to improve laboratory efficiency and operational performance. Strong emphasis on personalized medicine is also boosting demand for advanced diagnostic and biomarker testing services. Continued investment from both government and private sectors in biomedical research and clinical trials is further strengthening market growth. In addition, the rising burden of chronic conditions such as cancer and diabetes is increasing the need for comprehensive testing services, supporting sustained demand for central laboratory infrastructure across the United States.

Key companies operating in the Global Central Lab Market include Eurofins Scientific, ICON plc, Labcorp, IQVIA Laboratories, Quest Diagnostics, Thermo Fisher Scientific, Parexel International Corporation, Medpace, Inc., Cerba Research, ACM Global Laboratories, BioAgilytix Labs, Frontage Laboratories, LabConnect, Lambda Therapeutic Research, Medicover Integrated Clinical Services (MICS), and Versiti. Companies in the Central Lab Market are focusing on strengthening their market presence through continuous investment in advanced laboratory automation, digital transformation, and high-throughput testing capabilities. Many players are expanding their global laboratory networks to support increasing clinical trial activity across multiple regions. Strategic partnerships with pharmaceutical and biotechnology companies are enabling improved integration into drug development pipelines. Firms are also enhancing their service portfolios by incorporating advanced biomarker testing, genomic analysis, and specialized diagnostic solutions. In addition, companies are prioritizing data management systems and digital platforms to improve accuracy, traceability, and real-time reporting.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Services trends
  • 2.2.3 Application trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing emphasis on outsourcing of testing services
    • 3.2.1.2 Technological advancements in testing equipment
    • 3.2.1.3 Extensive growth in research and development investments
    • 3.2.1.4 Growth in global clinical trials
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent government regulations and compliance
    • 3.2.2.2 High operational and infrastructure costs
  • 3.2.3 Opportunities
    • 3.2.3.1 Integration of AI and advanced analytics
    • 3.2.3.2 Expansion into emerging and underserved markets
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 MEA
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends (Driven by Primary Research)
• 3.7 Impact of AI & generative AI on the market (Driven by Primary Research)
• 3.8 Pricing analysis, 2025 (Driven by Primary Research)
• 3.9 Gap analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis
• 3.12 Policy outlook

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis (Driven by Primary Research)
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Services, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Biomarker services
• 5.3 Anatomic pathology/histology
• 5.4 Microbiology services
• 5.5 Specimen management & storage
• 5.6 Genetic services
• 5.7 Other services

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Oncology
• 6.3 Neurology
• 6.4 Cardiology
• 6.5 Infectious diseases
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical and biotechnology companies
• 7.3 Academic and research institutes
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 MEA
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 ACM Global Laboratories
• 9.2 BioAgilytix Labs
• 9.3 Cerba Research
• 9.4 Eurofins Scientific
• 9.5 Frontage Laboratories
• 9.6 ICON plc
• 9.7 IQVIA Laboratories
• 9.8 LabConnect
• 9.9 Labcorp
• 9.10 Lambda Therapeutic Research
• 9.11 Medicover Integrated Clinical Services (MICS)
• 9.12 Medpace, Inc.
• 9.13 Parexel International Corporation
• 9.14 Quest Diagnostics
• 9.15 Thermo Fisher Scientific
• 9.16 Versiti